Anabolics: recent strategies for their detection and protection from inadvertent doping

Hans Geyer, Wilhelm Schänzer, Mario Thevis

ABSTRACT
According to the World Anti-Doping Agency (WADA) Prohibited List, anabolic agents consist of exogenous anabolic androgenic steroids (AAS), endogenous AAS and other anabolic agents such as clenbuterol and selective androgen receptor modulators (SARMs). Currently employed strategies for their improved detection include the prolongation of the detection windows for exogenous AAS, non-targeted and indirect analytical approaches for the detection of modified steroids (designer steroids), the athlete’s biological passport and isotope ratio mass spectrometry for the detection of the misuse of endogenous AAS, as well as preventive doping research for the detection of SARMs. The recent use of these strategies led to 4–80-fold increases of adverse analytical findings for exogenous AAS, to the detection of the misuse of new designer steroids, to adverse analytical findings of different endogenous AAS and to the first adverse analytical findings of SARMs. The strategies of the antidoping research are not only focused on the development of methods to catch the cheating athlete but also to protect the clean athlete from inadvertent doping. Within the past few years several sources of inadvertent doping with anabolic agents have been identified. Among these are nutritional supplements adulterated with AAS, meat products contaminated with clenbuterol, mycotoxin (zearalenone) contamination leading to zeranol findings, and natural products containing endogenous AAS. The protection strategy consists of further investigations in case of reasonable suspicion of inadvertent doping, publication of the results, education of athletes and development of methods to differentiate between intentional and unintentional doping.

INTRODUCTION
Since years anabolic agents are the most frequently detected doping substances in sports. This is also valid for 2012. Of 4500 adverse analytical and atypical findings reported by the World Anti-Doping Agency (WADA) accredited laboratories via the Anti-Doping Administration and Management System (ADAMS), about 50% are anabolic agents (figure 1). Anabolic agents are detected in all sports and they are mainly misused because of their anabolic effects such as muscle growth, increase of strength, accelerated recovery and anticitabolic effects under strenuous exercise.

According to the WADA Prohibited List, anabolic agents consist of exogenous anabolic androgenic steroids (AAS) including for instance stanozolol, methandienone, oxandrolone, etc., endogenous AAS such as testosterone, dehydroepiandrosterone, androstenedione, etc and other anabolic agents such as clenbuterol and selective androgen receptor modulators (SARMs).

Analytical challenges for the detection of the misuse of anabolic agents result from various different facts, among which a few are of major concern. These include the growing problem of the administration of unapproved and/or new designer substances, the evidently increasing use of endogenous substances, the constantly decreasing concentrations of the analytes detected in positive doping control samples (most probably due to the use of microdoses or to an earlier cessation of the drug regimen before doping controls are expected), and genetic polymorphisms that lead to different metabolic patterns in the tested individuals. Besides, major problems in connection with anabolic agents arise from ‘doping traps’, which can lead to inadvertent doping cases. Candidates for such traps are, for example, nutritional supplements adulterated with endogenous or exogenous AAS, food contaminated with clenbuterol and animal tissues used in traditional medicine therapeutics that contain endogenous AAS, etc. Here, the challenge obviously is to identify such sources of inadvertent doping to be able to warn and protect athletes.

Recent strategies to manage such challenges in connection with anabolic agents are presented.

Prolongation of the detection window for exogenous AAS
The detection of exogenous AAS is commonly based on the detection of their urinary phase-I and phase-II metabolites. Owing to the long lasting effects of AAS on athletic performance, the recent strategy of antidoping research is mainly focused on the search for long-term metabolites (LTM) of exogenous AAS. The implementation of LTM into the analytical screening procedures allows the prolongation of the detection window and an increased retrospectivity for AAS. In 1996 the first publications focused on LTM of exogenous AAS were published.4

The prolongation of the detection windows is not only due to the implementation of their LTM into sports drug testing but also to the use of highly sensitive detection methods employing chromatographic/mass spectrometric techniques (eg, LC-MS/MS, GC-MS/MS, HRMS) in screening procedures. The most recent methods, which combine LTM and new sophisticated mass spectrometric methods are compiled in table 1. These strategies of exploiting new analytical technologies and alternative target compounds have led to an enormous increase of adverse analytical findings (AAFs) in the past. For instance, the implementation of the LTM for metandienone (18-nor-17β-hydroxymethyl,
17α-methyl-androst-1,4,13-trien-3-one) in the screening procedure of the WADA accredited laboratory Cologne in 2006 resulted in an increase of AAFs with metandienone of more than 400% from approximately 12–15 AAFs in the years 2003–2005 to 68 AAFs in 2006, although the number and origin of the analysed samples was nearly constant (figure 2). As Cologne was the first WADA accredited laboratory in the world to screen for this new metabolite, the number of AAFs for metandienone in Cologne in 2006 was higher than the sum of AAFs for metandienone of all other WADA accredited laboratories.5 This effect of the implementation of new LTMs was even more pronounced with regard to the detection of AAFs for dehydrochloromethyltestosterone. In January 2013, three new LTMs for dehydrochloromethyltestosterone were implemented in the screening procedures of the Cologne laboratory (see table 1). This led to an increase of AAFs from an annual average number of 1–82 cases in the first 11 months of 2013 (figure 3). Only one or two of these 82 cases would have been detected with the methods used till the end of 2012 in the Cologne laboratory.

Another substantial increment in the number of AAFs was observed for the exogenous AAS stanozolol, also resulting from expanding the detection window for some of its metabolites (see table 1). Here, the use of high-resolution/high-accuracy mass spectrometry was considered decisive, which allowed for the detection of the stanozolol metabolite 3′-hydroxystanozolol-O-glucuronide in initial test methods at concentrations as low as 20 pg/mL; moreover, a pattern of other established as well as new stanozolol metabolites corroborated the findings, which included stanozolol-N-glucuronide, stanozolol-O-glucuronide, 16β-hydroxystanozolol-O-glucuronide, and 4β-hydroxyxystanozolol-glucuronide and the new LTM 17-epistanozolol-N-glucuronide. This screening method was implemented at the beginning of December 2012 in the Cologne laboratory and led to an increase of AAFs for stanozolol from an annual average of about 23 cases to 182 cases from early

---

Table 1 Recent methods for the prolonged detection of exogenous AAS by the combination of the implementation of LTMs in screening procedures and the use of sensitive mass spectrometric methods

<table>
<thead>
<tr>
<th>Exogenous AAS</th>
<th>LTMs</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metandienone</td>
<td>18-nor-17β-hydroxymethyl,17α-methyl-androst-1,4,13-trien-3-one</td>
<td>10, 59, 60</td>
</tr>
<tr>
<td></td>
<td>18-nor-17β-hydroxymethyl,17α-methyl-androst-1,4,13-trien-3-one-sulfate</td>
<td></td>
</tr>
<tr>
<td>Oxandrolone</td>
<td>17β-hydroxymethyl-17α-methyl-18-nor-2-oxa-5α-androsta-13-en-3-one</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>17α-hydroxymethyl-17β-methyl-18-nor-2-oxa-5α-androsta-13-en-3-one</td>
<td></td>
</tr>
<tr>
<td>Oxymetholone</td>
<td>18-nor-2x, 17β-hydroxymethyl-17α-methyl-5x-androst-13-en-3x-ol</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>18-nor-17β-hydroxymethyl-17α-2x-methyl-5x-androst-13-en-3-one</td>
<td></td>
</tr>
<tr>
<td>Desoxymethyltestosterone</td>
<td>18-nor-17,17-dimethyl-5x-androst-13-en-2x, 3x-diol</td>
<td>7</td>
</tr>
<tr>
<td>Dehydrochloromethyltestosterone</td>
<td>4-chloro-17-methyl-5β-androstan-3,16,17-triol</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>4-chloro-17-hydroxymethyl-17-methyl-18-nor-5β-androst-1,13-diene-3-ol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4-chloro-17-hydroxymethyl-17-methyl-18-nor-5β-androst-13-ene-3-ol</td>
<td></td>
</tr>
<tr>
<td>Stanozolol</td>
<td>Stanozolol-N-glucuronide</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Stanozolol-O-glucuronide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epistanozolol-N-glucuronide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3′-Hydroxystanozolol-O-glucuronide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>16β-Hydroxystanozolol-O-glucuronide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4β-Hydroxystanozolol-O-glucuronide</td>
<td></td>
</tr>
</tbody>
</table>

AAS, anabolic androgenic steroids; LTMs, long-term metabolites.

Figure 1 Adverse analytical findings and atypical findings of all World Anti-Doping Agency (WADA) accredited laboratories in 2012 reported via Anti-Doping Administration and Management System (ADAMS)."
A novel approach was received by the substance tetrahydrogestrinone (THG), which was detected in connection with the BALCO case in 2003 and identified by the WADA-accredited laboratory in Los Angeles. From 2002 until 2008 a total of 22 steroidal compounds, arguably modified to remain undetected in doping controls, were identified by WADA-accredited laboratories and the need to complement target-oriented analytical methods as usually employed in routine sports drug testing by non-targeted approaches had become evident. Consequently, strategies to combat the purported as well as proven abuse of designer steroids have been evaluated, two of which were particularly promising: the non-targeted approach focusing on the detection of characteristic and common fragment/product ions derived from conserved nuclei of AAS, and the indirect approach based on monitoring the biological effect of AAS on the profile of endogenous steroids.

Non-targeted and indirect analytical approaches for the detection of modified steroids (designer steroids)

‘Tailored’ steroidal agents with assumed (or proven) anabolic-androgenic properties have become a predominant issue for doping control laboratories since the early 2000s. Commonly referred to as ‘designer steroids’, these compounds are not approved therapeutics and, largely, have also not undergone clinical trials. One of the first designer steroids, detected in a nutritional supplement, was 3β-hydroxyandrost-4-ene-7,17-dione. The most public attention however was received by the substance tetrahydrogestrinone (THG), which was detected in connection with the BALCO case in 2003 and identified by the WADA-accredited laboratory in Los Angeles. From 2002 until 2008 a total of 22 steroidal compounds, arguably modified to remain undetected in doping controls, were identified by WADA-accredited laboratories and the need to complement target-oriented analytical methods as usually employed in routine sports drug testing by non-targeted approaches had become evident. Consequently, strategies to combat the purported as well as proven abuse of designer steroids have been evaluated, two of which were particularly promising: the non-targeted approach focusing on the detection of characteristic and common fragment/product ions derived from conserved nuclei of AAS, and the indirect approach based on monitoring the biological effect of AAS on the profile of endogenous steroids.

Non-targeted approach

Naturally occurring endogenous androgens are well defined and known from the basis of thousands of annual doping control samples worldwide. Hence, a viable approach towards uncovering the presence of derivatives of testosterone and its synthetic analogues has been the screening for commonalities of steroidal agents by means of mass spectrometry and to flag those peaks that are not normally seen in doping control samples. Triggered by the aforementioned BALCO scandal and the identified THG, studies concerning a substantial variety of known AAS were conducted. As illustrated in figure 5, this approach allowed for the identification of structure-specific product ions such as m/z 241 of gestrinone and its derivatives. In addition, testosterone derivatives frequently yield A/B-ring specific product ions at m/z 97 and 109, trenbolone analogues result in abundant product ions at m/z 227, and other specifics allow to generally detect and characterise structural features of subgroups of AAS. Employing LC-MS/MS in precursor ion scan mode, diagnostic product ions (such as the aforementioned species) can lead to respective precursor ions and support the detection of designer variants of established doping agents. This approach was successfully applied to routine doping controls enabling the revealing of the misuse of the trenbolone analogue methyltrebolone (methyltrenbolone) in 2008, resulting in the detection and subsequent identification of the drug in 11 weightlifters before the Olympic Games in Beijing. Further studies on generic dissociation patterns of steroidal agents were conducted, suggesting the use of product ions obtained through higher sensitivities of the MS analyser for deuterated substances (requiring accuracy and retrospectivity).

Figure 2: Adverse analytical findings for metandienone in the World Anti-Doping Agency (WADA) accredited laboratory Cologne before and after the prolongation of the detection window for metandienone by the implementation of a new long-term metabolite in the screening procedure in January 2006.

Figure 3: Adverse analytical findings for dehydrochloromethyltestosterone in the World Anti-Doping Agency (WADA) accredited laboratory Cologne before and after the prolongation of the detection window for dehydrochloromethyltestosterone by the implementation of three new long-term metabolites in December 2012 in the screening procedure (status from 1 December 2013).

Figure 4: Adverse analytical findings for stanozolol in the World Anti-Doping Agency (WADA) accredited laboratory Cologne before and after the prolongation of the detection window for stanozolol by the use of high-resolution mass spectrometry in combination with the implementation of old and new stanozolol metabolites and a new long-term metabolite in December 2012 (status from 1 December 2013).
Figure 5  Non-targeted analysis (precursor ion scan): screening for a common fragment of different steroids (m/z 241).

The indirect approach for the detection of designer steroids is based on endocrinological feedback mechanisms and the effect of these steroids on the profile of urinary endogenous steroids (steroid profile), which is monitored for each athlete within the Athlete’s Biological Passport (ABP, vide infra). It is well known that the administration of AAS leads to a suppression of the excretion of endogenous steroids.25 26 Therefore, suppressed endogenous steroid concentrations may trigger a search for unknown designer steroids. This strategy was successfully applied in the detection of the misuse of norbolethone in 2002,27 where unusual steroid profiles suggested the misuse of a yet unknown (or at least not screened) AAS. However, the determination of arguably steroid abuse-influenced urinary steroid profiles does not allow for reporting an AAF. The administered drug still needs to be identified; nevertheless, the suspicion resulting from steroid profile analyses is of great importance in target testing of athletes and further investigations of the collected doping control urine samples.

The ABP approach and isotope ratio mass spectrometry for the detection of the misuse of endogenous AAS

For approximately 30 years the misuse of endogenous AAS is detected via alterations in the urinary steroid profile.28 The main parameters of the steroid profile as analysed in doping control laboratories are the concentrations and ratios of the glucuronidated testosterone metabolites androstosterone, 17α-androstane-3α,17β-diol and 5β-androstane-3α, 17β-diol as well as the glucuronidated epitestosterone, which originates from the biosynthesis of testosterone. Among these parameters the best elucidated and investigated item is the ratio of testosterone and epitestosterone (T/E) which was introduced in doping controls by Donike et al.29 to provide a means to detect the misuse of testosterone. The administration of testosterone and other endogenous steroids leads to ‘abnormal’ steroid profiles, for example, abnormally increased T/E ratios. The first strategies to differentiate between normal and abnormal steroid profiles were based on population-based reference limits. With the growing knowledge of individuals with naturally abnormal steroid profiles, for example, naturally increased or decreased T/E ratios, the strategy changed from the use of population-based evaluation towards individual reference ranges.30 The establishment of individual reference ranges was first adopted by UCI in the mid-1990s to identify individuals with naturally elevated T/E ratios to prevent false-positive cases. This was carried out by means of so-called endocrinological studies.31 The combination of the application of population-based and individual reference ranges led to one of the biggest doping scandals in the mid 1990s when during the Asian Games 1994 in Hiroshima, Japan, nine gold medallists were sanctioned for doping with the endogenous AAS dihydrotestosterone.32

To globalise this strategy, that is, to be able to compare steroid profiles analysed at different locations, WADA and the accredited doping control laboratories harmonised the employed analytical methods. Additionally the ADAMS was further developed to enable combining the collected steroid profiles of all doping control samples and the direct comparison with individual and population based reference ranges. The calculation of the individual reference ranges is performed on the basis of the adaptive model developed by Sottas et al.33 34 All these elements are now adopted in the steroidal module of the ABP approach. Together with the increasing knowledge about factors influencing the steroid profile, for example, pharmaceutical, genetic, pathological, analytical, medical and other aspects,35 this strategy has proven fit-for-purpose to support detecting the misuse of endogenous AAS. The steroidal ABP is an open system and additional urinary steroids and ratios can be used for the decision-making process.35–37 An invaluable addition to this strategy is the use of the isotope ratio mass spectrometry (IRMS). This technique allows to differentiate between natural and synthetic endogenous steroids by means of the ratios of the stable carbon isotopes 13C and 12C,38 39 that is, a suspicion of the misuse of endogenous AAS, triggered by the steroidal module of the ABP, can be proven by subsequent IRMS analyses.
Preventive doping research approach for the detection of SARMs

Being categorised as ‘other anabolic agents’, SARMs have been prohibited according to WADA’s regulations since 2008. Owing to their proven anabolic properties and ability to stimulate the androgen receptor in muscle and bone, a substantial misuse potential was identified. This might be even more fuelled by the fact that SARMs inhibit androgen receptor activity in other organs (eg, skin and prostate) and have demonstrated less (or at least other) undesirable effects on the human organism than AAS. Numerous SARMs have been subjected to preclinical and clinical trials since the first non-steroidal representatives of this new class of therapeutics were introduced in 1998.40 The number of new drug (or chemical) entities with SARM-like properties has been growing constantly and reviews on recent developments are frequently published41; however, full clinical approval has not been accomplished for any of the drug candidate SARMs yet, although the arylpropionamide-derived therapeutic Ostarine (figure 6B) has been in phase-III clinical trials and might be launched for specific interventions in the near future. In fact, numerous potential candidates were discontinued, arguably due to unacceptable side effects. A selection of 10 SARM substances is depicted in figure 6, illustrating the chemical heterogeneity and thus the analytical challenge for sports drug testing laboratories for these emerging compounds.

Although not yet marketed, SARMs are prohibited and their therapeutic profile has certainly justified the proactive method development for detecting these analytes as comprehensive as possible in routine doping controls. As such, SARMs have been a matter of preventive doping research, and first assays allowing for the analysis of arylpropionamide-derived SARMs (such as Andarine and Ostarine) were published in 2006.42 In the subsequent years, a great variety of additional though structurally different SARM candidates were presented in scientific articles as well as patents. Representatives of these were studied concerning their traceability in sports drug testing samples including blood and urine,43 44 largely requiring their chemical synthesis due to limited/non-availability of reference material. Moreover, their metabolism was investigated using in vitro or animal in vivo models to provide potential target analytes for efficient urine doping controls.45 The relevance of the work was demonstrated soon after as SARM drug candidates including the officially discontinued Andarine were offered and sold by Internet-based suppliers.46 47 and first AAFs with Andarine were reported in 201048 and 2011.49 These findings highlight the importance of preventive doping research and the options given to antidoping authorities to reduce cheating athletes’ windows of opportunity to abuse yet non-approved drugs. It is however a task of substantial complexity and benefits greatly from constructive collaborations with partners in the pharmaceutical industry, at European (EuMoCEDA) and international (WADA) level.

Protection of athletes from inadvertent doping with anabolic agents

Within the past few years, several sources of inadvertent doping with anabolic agents have been identified. Among these are nutritional supplements adulterated with AAS, meat products contaminated with clenbuterol and natural products containing endogenous AAS. Since about 2003 a great number of nutritional supplements have become available, advertised with claims of enormous muscle growth and increase in strength. According to the advertisements and the labels these biological effects are attributed to new ingredients and formulae with fantasy-derived and unapproved names. The analyses of many of these products has shown that they contain exogenous AAS such as metandienone,

Figure 6 Chemical structures of selected selective androgen receptor modulator drug candidates: andarine (A), ostarine (B), BMS-564929 (C), 4-(7-hydroxy-1,3-dioxo-tetrahydro-pyrrolo[1,2-c]imidazol-2-yl)-naphtalene-1-carbonitrile (D), LGD-121071 (E), LGD-2226 (F), S-40503 (G), 2-methyl-2-(8-nitro-3a,4,5,9b-tetrahydro-3H-cyclopenta[clchinolin-4-yl)propan-1-ol (H), RAD140 (I), and ACP-105 (J).
Stanozolol, oxandrolone and dehydrochloromethyltestosterone in therapeutic or even supratherapeutic doses, not declared on the label. Also nutritional supplements adulterated with clenbuterol have been detected, which were additionally advertised with their fat burning effects. The consumption of such supplements inevitably leads to AAFs and is connected with considerable health risks. Criminal nutritional supplement producers use this strategy to establish their ineffective products in the sports market. To prevent inadvertent doping cases athletes should avoid the consumption of nutritional supplements, which are advertised with extreme claims of muscle growth, increase of strength and fat loss. The best strategy to overcome this problem seems to be the appropriate education of athletes.

A further source of inadvertent doping, which attracted attention within the past 3 years was meat contaminated with clenbuterol. The anabolic agent clenbuterol has been evidently misused as growth promoter in cattle feeding in selected countries and meat originating from these farms can contain traces of clenbuterol leading to AAFs or even poisonings. In 2010 and 2011 unexplainable doping cases with clenbuterol of groups of athletes in table tennis and soccer led to investigations of the origin of these findings. It could be shown that the travel and stay in China and Mexico was connected with a high risk of inadvertent doping with clenbuterol. The most probable source is contaminated meat but other animal products such as milk or offal cannot be excluded. Also other risk countries might exist. The antidoping research, which also includes investigations to protect athletes from inadvertent doping, is now focused on the development of methods to differentiate between clenbuterol originating from medication and from contaminated meat. Promising results are provided by studies of pharmacokinetics and metabolism of clenbuterol. The most probable source is contaminated meat but other animal products such as milk or offal cannot be excluded. Also other risk countries might exist. The antidoping research, which also includes investigations to protect athletes from inadvertent doping, is now focused on the development of methods to differentiate between clenbuterol originating from medication and from contaminated meat. Promising results are provided by studies of pharmacokinetics and metabolism of clenbuterol.

Similar to the clenbuterol contamination issue, the unintentional intake of the mycotoxin zearalenone can result in AAFs concerning one of its human urinary metabolites referred to as zeranol. Zeranol has been prohibited according to the regulations of WADA as an anabolic agent and its formation from zearalenone in case of suspicious test results, which confirmed zearalenone as the origin of zeranol findings in 2011.

A very unusual source of arguably inadvertent doping with anabolic agents was detected during the FIFA women’s World Cup 2011 in soccer. Five players of a team were tested positive for endogenous AAS. The AAFs were detected by means of atypical steroid profiles and confirmed by positive IRMS results. Extracts and grains of deer musk pods were identified as source of the positive results. These animal products contained huge amounts of 16 different endogenous AAS of which 9 were listed on the WADA Prohibited List 2011 (see figure 7). These musk deer products were claimed to be used by the team to increase mental strength without knowing that the consumption leads to AAFs.

These examples show that antidoping research is not only focused on the development of methods to catch the cheating athlete but also to protect the clean athlete. The protection strategy consists of the following steps: further investigations in case of reasonable suspicion of inadvertent doping, publication of the results, education of athletes, development of methods to differentiate between intentional and inadvertent doping.

### Important aspects of this review are

- Anabolic agents remain the most frequently detected class of doping agents in elite sport.
- A significant increase in findings has been observed whenever new target analytes for improved retrospectivity were introduced.
- New, emerging therapeutics of non-steroidal structure have entered the illicit market and have been detected recently in sports drug testing.
- Analytical strategies largely rely on steroid profiling and target analyte detection with continuously improving detection windows.
Contributors HK, WS and MT contributed equally to the different review chapters with literature review, data compiling and preparation of the manuscript.

Competing interests None.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES


56 Segura I. Is anti-doping analysis so far from clinical, legal or forensic targets?: The added value of close relationships between related disciplines. Drug Test Anal 2009;1:479–84.


Anabolic agents: recent strategies for their detection and protection from inadvertent doping

Hans Geyer, Wilhelm Schänzer and Mario Thevis

doi: 10.1136/bjsports-2014-093526

Updated information and services can be found at:
http://bjsm.bmj.com/content/48/10/820

**References**  
These include:

**Open Access**  
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**Email alerting service**  
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**  
Articles on similar topics can be found in the following collections  

BJSM Reviews with MCQs (210)  
Open access (277)

**Notes**

To request permissions go to:  
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:  
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:  
http://group.bmj.com/subscribe/